Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues
Why the study?
Cancer treatment associated cardiotoxicity (CTAC) increasingly burdens cancer survivors, but published data on biomarkers are inconsistent and recommendations remain mostly based on expert consensus.
Can cardiac biomarkers (cTn and BNP) integrated with cardiac imaging predict and detect subclinical cardiotoxicity in cancer patients undergoing antineoplastic treatment?
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Cardiac biomarkers may aid early CTAC detection in survivors; leaves open prospective validation before routine use.
Structured PICO
Can cardiac biomarkers (cTn and BNP) integrated with cardiac imaging predict and detect subclinical cardiotoxicity in cancer patients undergoing antineoplastic treatment?
P
Population
Cancer patients undergoing antineoplastic treatment at risk of cancer treatment associated cardiotoxicity (CTAC)
I
Intervention
Cardiac biomarkers (cardiac troponin and B-type natriuretic peptide) integrated with cardiac imaging
O
Outcome
Detection of subclinical cardiotoxicity (CTAC)surrogate
Cardiac biomarkers such as troponin and BNP, especially when integrated with cardiac imaging, are valuable tools for the early detection of cancer treatment-associated cardiotoxicity.
Limitations
- Inconsistent data from published studies
- Recommendations mostly based on expert consensus opinion
Cite This Study
Bračun et al. (2020) studied this question.